Johnson & Johnson raised its full-year sales and adjusted earnings forecasts after third-quarter revenue increased 5.9% to $25.4 billion, while reported profit fell sharply because of a talc litigation charge and transactions.
Net earnings declined to $210 million, or 9 cents per diluted share, from $5.15 billion, or $2.12 per share, a year earlier. Results reflected a special charge for a proposed talc litigation resolution, the Firefly Bio acquisition and a collaboration with Sail Biomedicines.
Adjusted earnings, which exclude intangible amortization and special items, fell to $6.34 billion from $6.80 billion. Adjusted earnings per share declined to $2.59 from $2.80 and included effects from the transactions.
Innovative Medicine sales totaled $16.76 billion, compared with $15.56 billion a year earlier. Excluding currency movements, sales grew 7.9%, driven by products including Tremfya, Darzalex, Carvykti, Tecvayli, Spravato and Caplyta. Declines in Stelara and other medicines partially offset growth.
MedTech sales reached $8.64 billion, up from $8.43 billion. Operational growth of 2.5% reflected demand for electrophysiology products, Shockwave cardiovascular technology, contact lenses and orthopedic trauma products.
U.S. sales rose to $14.96 billion from $13.71 billion, while international sales increased to $10.44 billion from $10.29 billion.
For 2026, J&J now expects reported sales of $101 billion to $101.4 billion, raising the midpoint to $101.2 billion. Adjusted earnings guidance increased to $11.05 to $11.15 per share, with the midpoint rising 6 cents to $11.10.
The company also cited U.S. authorization of its Ottava surgical robot and approval of Imaavy for warm autoimmune hemolytic anemia among recent regulatory developments.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!